falsefalse

The Evolving Treatment Paradigm for Stage I-IIIA NSCLC - Episode 4

Updates in the Treatment of Stage I-IIIA NSCLC

, , , ,

The panel reviews updates in the treatment of stage I-IIIA NSCLC and discusses its impact in clinical practice.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: Recommendations for Molecular Testing in Non-Small Cell Lung Cancer (NSCLC)
    EP. 2: Molecular Testing in Early NSCLC to Guide Treatment Decision Making
    EP. 3: Is There a Role for Liquid Biopsies in Early NSCLC?
    Now Viewing
    EP. 4: Updates in the Treatment of Stage I-IIIA NSCLC
    EP. 5: The Role of Neoadjuvant Therapy in Patients with Resectable NSCLC
    EP. 6: Selecting Appropriate Patients with NSCLC for Neoadjuvant Therapy
    EP. 7: The Role of Adjuvant Therapy in Patients with NSCLC
    EP. 8: Updates on Adjuvant Osimertinib for NSCLC Treatment from the ADUARA Trial
    EP. 9: Adjuvant Therapy in EGFR-Mutated NSCLC
    EP. 10: NSCLC Molecular Testing Recommendations for Community Hospitals
    EP. 11: Exciting NSCLC Data Updates from ESMO 2022

    Related Content:

    The Evolving Treatment Paradigm for Stage I-IIIA NSCLCLung CancerOncLive Peer Exchange®
    Obrixtamig Could Broaden the Reach of DLL3/CD3-Targeted BiTEs in Small Cell Lung and Other Neuroendocrine Cancers
    Targeted Therapy Developments and Screening Updates Broaden the NSCLC Treatment Paradigm
    Ventana TROP2 (EPR20043) RxDx Device Receives FDA Breakthrough Device Designation for Dato-DXd Selection in NSCLC
    x